HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1

被引：0

作者：

Braso-Maristany, F. ^{[1
]}

Griguolo, G. ^{[2
]}

Chic, N. ^{[3
]}

Pare Brunet, L. ^{[3
]}

Galvan, P. ^{[4
]}

Dieci, M. V. ^{[5
]}

Miglietta, F. ^{[6
]}

Giarratano, T. ^{[7
]}

Martinez-Saez, O. ^{[8
]}

Marin, M. ^{[8
]}

Vidal Losada, M. J. ^{[9
]}

Adamo, B. ^{[10
]}

Munoz, M. ^{[11
]}

Vivancos, A. ^{[12
]}

Villagrasa Gonzalez, P. ^{[13
]}

Parker, J. ^{[13
]}

Perou, C. M. ^{[14
]}

Conte, P. F. ^{[15
]}

Prat, A. ^{[16
]}

Guarneri, V. ^{[17
]}

机构：

[1] IDIBAPS Inst Invest Biomed August Pi & Sunyer, Dept Oncol, Barcelona, Spain

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[3] Reveal Genom SL, Dept Sci, Barcelona, Spain

[4] IDIBAPS August Pi & Sunyer Biomed Res Inst, Dept Med Oncol, Barcelona, Spain

[5] Univ Padua, DiSCOG, Padua, Italy

[6] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol, Padua, Italy

[7] IOV Ist Oncologico Veneto IRCCS, Dept Oncol, Padua, Italy

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Hosp Clin Barcelona, Breast Canc, Barcelona, Spain

[10] Hosp Clin Prov Barcelona, Breast Canc Dept, Barcelona, Spain

[11] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[12] Vall Hebron Univ sity Hosp, Genom Dept, Barcelona, Spain

[13] UNC, Dept Oncol, Lineberger Canc Ctr, Chapel Hill, NC USA

[14] UNC, Dept Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[15] IOV Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol Dept, Padua, Italy

[16] Hosp Clin Prov Barcelona, Dept Med Oncol, Barcelona, Spain

[17] Univ Padua, Oncol & Gastroenterol Dept, Dept Surg, Padua, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.276

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

237P

引用

页码：S646 / S646

页数：1

共 50 条

[21] T-DM1 in HER2-positive breast cancer brain metastases (BM).
Bartsch, Rupert
Berghoff, Anna Sophie
Rudas, Margareta
Bergen, Elisabeth
Gnant, Michael
Dieckmann, Karin
Pinker, Katja
Zielinski, Christoph
Steger, Guenther G.
Preusser, Matthias
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] Activity of T-DM1 in Her2-positive breast cancer brain metastases
Bartsch, Rupert
Berghoff, Anna S.
Vogl, Ursula
Rudas, Margaretha
Bergen, Elisabeth
Dubsky, Peter
Dieckmann, Karin
Pinker, Katja
Bago-Horvath, Zsuzsanna
Galid, Arik
Oehler, Leopold
Zielinski, Christoph C.
Gnant, Michael
Steger, Guenther G.
Preusser, Matthias
CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (07) : 729 - 737
[23] T-DM1 is active in Her2-positive breast cancer brain metastases
Bartsch, R.
Berghoff, A.
Rudas, M.
Bergen, E.
Gnant, M.
Dieckmann, K.
Pinker, K.
Zielinski, C. C.
Steger, G. G.
Preusser, M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 195 - 195
[24] Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial
Braso-Maristany, F.
Martinez Saez, O.
Pare Brunet, L.
Marin-Aguilera, M.
Conte, P. F.
Jares, P.
Guarneri, V.
Pascual, T.
Puig-Butille, J. A.
Vivancos, A.
Parker, J.
Villagrasa Gonzalez, P.
Tolaney, S. M.
Carey, L. A.
Perou, C. M.
Prat, A.
ANNALS OF ONCOLOGY, 2022, 33 : S134 - S135
[25] Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
Ma, Bo
Ma, Qianqian
Wang, Hongqiang
Zhang, Guolei
Zhang, Huiying
Wang, Xiaohong
ONCOTARGETS AND THERAPY, 2016, 9 : 959 - 976
[26] Pertuzumab and T-DM1: New perspectives in the treatment of HER2-positive breast cancer
Guiu, S.
Fumoleau, P.
ONCOLOGIE, 2015, 17 (5-6) : 263 - 270
[27] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
Matsui, K.
Yoshikawa, A.
Oyama, K.
Nozaki, Z.
Tanada, Y.
Earashi, M.
Kiyohara, K.
Nagata, T.
Fukushima, W.
Shimizu, T.
Maeda, K.
ANNALS OF ONCOLOGY, 2017, 28
[28] EXPOSURE-RESPONSE ANALYSIS IN PATIENTS WITH HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) TO ASSESS THE EFFECT OF T-DM1 ON QTC PROLONGATION
Gupta, M.
Wang, B.
Carrothers, T.
Joshi, A.
LoRusso, P. M.
Chu, W.
Shih, T.
Loecke, D.
Girish, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S58 - S58
[29] RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM)
Berghoff, A. S.
Bartsch, R.
Bergen, E.
Rudas, M.
Gnant, M.
Dieckmann, K.
Pinker, K.
Zielinski, C. C.
Steger, G. G.
Preusser, M.
NEURO-ONCOLOGY, 2014, 16
[30] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Hunter, Francis W.
Barker, Hilary R.
Lipert, Barbara
Rothe, Francoise
Gebhart, Geraldine
Piccart-Gebhart, Martine J.
Sotiriou, Christos
Jamieson, Stephen M. F.
BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612

← 1 2 3 4 5 →